Milatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Milatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD74
Clinical data
Legal status ?
Identifiers
CAS number 899796-83-9 N
ATC code None
UNII 2OP4E0GC6V YesY
KEGG D08944 YesY
Chemical data
Formula C6518H10066N1758O2020S40 
Mol. mass 146.7 kDa
 N (what is this?)  (verify)

Milatuzumab is a monoclonal antibody for the treatment of multiple myeloma and other hematological malignancies.[1]

This drug was developed by Immunomedics, Inc.

It has been linked to doxorubicin to form an antibody-drug conjugate for treatment of relapsed multiple myeloma. A phase I/II clinical trial has started.[2]

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council – Milatuzumab, American Medical Association.
  2. ^ "Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma". 16 June 2010.